A*STAR Singapore Immunology Network (A*STAR SIgN)

Leveraging on its public sector and industry collaborations, A*STAR and the Experimental Drug Development Centre hold the keys to effective drug discovery and development.

Booster shots with COVID-19 mRNA outperformed inactivated virus by eliciting stronger antibody responses to the Omicron variant.

Drug-resistant malarial parasites form flower-like structures to shield themselves from attack by antimalarial drugs and the immune system.

A*STAR scientists decipher how a stem cell-based treatment stops the uncontrolled inflammation associated with severe COVID-19 cases.

A T cell therapy innovation may offer new hope for acute myeloid leukemia patients who relapse after conventional treatment.

Using a new genome analysis technology, A*STAR scientists discover never-before-seen immune responses in tuberculosis infections.

More evidence emerges that fatty foods change skin composition, creating the perfect conditions for acne flare-ups.

A profile of the immune responses from Singaporean patients recovered from COVID-19 has revealed an urgent need to update vaccines against new viral variants.

A deletion in the genome of SARS-CoV-2 variants makes resulting infections milder and could also be a target for future COVID-19 treatments.

A*STAR researchers discover a mechanism that fires up the metabolism of cancer-killing immune cells, paving the way for future cancer immunotherapies.

Game-changing new ideas and products are born from connecting the right minds and hands. In this cover story, we spotlight how A*STAR facilitates those connections and cultivates the culture needed for an ecosystem of innovation.

The identification of a class of inflammatory immune cells offers new opportunities to treat chronic skin conditions.